These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929 [TBL] [Abstract][Full Text] [Related]
27. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960 [TBL] [Abstract][Full Text] [Related]
28. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides. Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436 [TBL] [Abstract][Full Text] [Related]
29. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051 [TBL] [Abstract][Full Text] [Related]
30. Surface Plasmon Resonance Assay of Binding Properties of Antisense Oligonucleotides to Serum Albumins and Lipoproteins. Onishi R; Watanabe A; Nakajima M; Sekiguchi M; Kugimiya A; Kinouchi H; Nihashi Y; Kamimori H Anal Sci; 2015; 31(12):1255-60. PubMed ID: 26656814 [TBL] [Abstract][Full Text] [Related]
31. Gapmer Antisense Oligonucleotides to Selectively Suppress the Mutant Allele in COL6A Genes in Dominant Ullrich Congenital Muscular Dystrophy. Aguti S; Marrosu E; Muntoni F; Zhou H Methods Mol Biol; 2020; 2176():221-230. PubMed ID: 32865794 [TBL] [Abstract][Full Text] [Related]
32. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding. Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959 [TBL] [Abstract][Full Text] [Related]